The National Health Insurance Administration (NHIA) will evaluate including a one-time gene therapy to treat individuals with hemophilia B in the NHI drug reimbursement scheme after it is approved in Taiwan, an NHIA official said Monday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
Shinzo Abe's widow thanks Taiwan for commemorating late husband
06/21/2025 09:50 PM - Society
Taiwan Railway to end 75% discount for children with disabilities
06/21/2025 09:27 PM - Business
Taiwan cleanroom firms see orders surge as chipmakers expand overseas
06/21/2025 08:33 PM - Politics
Explainer: Mass slate of recall votes leaves KMT staring down disaster
06/21/2025 08:26 PM - Politics
KMT claims recall vote petitions contain forgeries
06/21/2025 06:36 PM